Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

NARecruitingINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2030

Conditions
First-episode Psychosis
Interventions
OTHER

Recorded interview

A recorded clinical interview, transcribed verbatim and blinded analyzed

OTHER

Clinical scales

Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)

BIOLOGICAL

Blood sample

Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.

Trial Locations (6)

29017

NOT_YET_RECRUITING

Dr Sonia MARSELLA, Quimper

29609

RECRUITING

Dr Florian STEPHAN, Brest

35703

NOT_YET_RECRUITING

Dr Dominique DRAPIER, Rennes

37044

NOT_YET_RECRUITING

Dr Vincent CAMUS, Tours

44093

NOT_YET_RECRUITING

Dr Anne SAUVAGET, Nantes

49033

NOT_YET_RECRUITING

Dr Bénédicte GOHIER, Angers

All Listed Sponsors
lead

University Hospital, Brest

OTHER

NCT05384392 - Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode | Biotech Hunter | Biotech Hunter